Nuveen Asset Management LLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Nuveen Asset Management LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 25,028 shares of the company's stock, valued at approximately $436,000.

Other institutional investors have also added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth $31,000. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics in the 4th quarter worth about $32,000. Legal & General Group Plc purchased a new stake in Bicara Therapeutics in the 4th quarter valued at about $33,000. Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics in the 4th quarter valued at about $35,000. Finally, Virtus ETF Advisers LLC bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $69,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reaffirmed an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday, May 23rd. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Finally, Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $31.86.

Bicara Therapeutics Trading Down 0.2%

BCAX traded down $0.02 on Monday, reaching $11.48. The company had a trading volume of 746,497 shares, compared to its average volume of 585,117. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $28.09. The business has a 50 day simple moving average of $12.32 and a 200 day simple moving average of $14.08.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28). Sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.